Dextromethorphan potentiator for anticonvulsant composition and method
AssigneeNova Pharmaceutical Corporation
InventorsMichael J. Pontecorvo, John W. Ferkany
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprises an anti-epileptic drug that does not inhibit, enhance or otherwise modify dextromethorphan binding to the central nervous system dextromethorphan receptor and an effective amount of dextromethorphan to potentiate the anticonvulsant activity of the drug. Other related compounds similar to dextromethorphan which inhibit or enhance dextromethorphan binding to the dextromethorphan site in the brain are also suitable as potentiating agents for the anticonvulsants. A method of treating epilepsy and other convulsions include the steps of introducing to the patient an effective amount of the compound comprising an anti-epileptic drug and potentiating amount of dextromethorphan or one of the related compounds.
Claims10
A method of treating epilepsy and other convulsions including administering an effective amount of a pharmaceutical composition comprising:
- (a) an effective amount of about 80 mg to 1600 mg per day of an anticonvulsant compound that does not bind to the central nervous system dextromethorphan receptor site;
- and
- (b) an effective amount of a potentiating agent that binds to the dextromethorphan receptor site selected from the group consisting of dextromethorphan, benztropine, caramiphen, carbetapentane, chlorpromazine, dimethoxanate, flupenthixol, fluphenazine, opiramol, perphenazine, pipazethate, prochlorperazine, promethazine, trifluoperazine, trimeprazine, noscapine, cinnarizine, phenylamine and the pharmaceutically acceptable salts thereof.
A method of treating convulsions in an animal including administering:
- (a) an anticonvulsant dosage of about 80 mg to 1600 mg per day of carbamazepine;
- and
- (b) an effective amount of a potentiating agent selected from the group consisting of dextromethorphan, benztropine, caramiphen, carbetapentane, chlorpromazine, dimethoxanate, flupenthixol, fluphenazine, opipramol, perphenazine, pipazethate, prochlorperazine, promethazine, trifluoperazine, trimeprazine, noscapine, cinnarizine, phenylamine and the pharmaceutically acceptable salts thereof.
An anticonvulsant pharmaceutical composition comprising:
- (a) an anticonvulsant dosage of about 80 mg to 1600 mg per day carbamazepine;
- and
- (b) an effective amount of a potentiating agent selected from the group consisting of dextromethorphan, benztropine, caramiphen, carbetapentane, chlorpromazine, dimethoxanate, flupenthixol, fluphenazine, opipramol, perphenazine, pipazethate, prochlorperazine, promethazine, trifluoperazine, trimeprazine, noscapine, cinnariazine, phenylamine and the pharmaceutically acceptable salts thereof.
An anticonvulsant composition comprising:
- (a) an effective potentiating amount of dextromethorphan, benztropine, caramiphen, carbetapentane, chlorpromazine, dimethoxanate, flupenthixol, fluphenazine, opipramol, perphenazine, pipazethate, prochlorperazine, promethaine, trifluoperazine, trimeprazine, noscapine, cinnarizine and phenylamine;
- and
- (b) an anticonvulsant dosage of about 80 mg to 1600 mg per day of carbamazepine,
An anticonvulsant pharmaceutical composition comprising:
- (a) an 80 mg to 1600 mg per day dosage of carbamazepine or other anticonvulsant which is capable of binding to the N-methyl-D-aspartate receptor site;
- and
- (b) a potentiating amount of dextromethorphan, benztropine, caramiphen, carbetapentane, chlorpromazine, dimethoxanate, flupenthixol, fluphenazine, opipramol, perphenazine, pipazethate, prochlorperazine, promethazine, trifluoperazine, trimeprazine, noscapine, cinnarizine, phenylamine and pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.